Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections

Current Opinion in Infectious Diseases

Volumn 14, Issue 2, 2001, Pages 165-172

  Andes, D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFAZOLIN; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CEFPROZIL; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; SPARFLOXACIN; TIMENTIN; TROVAFLOXACIN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL MUTATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRACTICE GUIDELINE; PREDICTION; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0035083697     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200104000-00010     Document Type: Review

References (53)

1. Pharmacokinetic/pharmacodynamics parameters: Rationale for antibacterial dosing of mice and men
2. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations
3. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
4. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
5. The in-vivo postantibiotic effect in a thigh infection in neutropenic mice
6. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models
7. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against Gram-negative bacilli in murine thigh-infection and pneumonitis models
8. Pharmacodynamic activity of a new oxazolidinone in an animal infection model
9. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins
10. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
11. Differences in time above MIC required for efficacy of beta-lactams in animal infection models
12. Interrelationships between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
13. Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: Implications for breakpoint determinations
14. Pharmacodynamics of fluoroquinolones in expimental animals
15. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
16. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
17. Pharmacodynamics of fiuoroquinolones against Streptococcus pneumoniae: Analysis of phase-III clinical trials
18. Levofloxacin treatment failure of pneumococcal pneumonia and development of resistance during therapy
19. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media
20. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children
21. Bacteriological and clinical efficacy of a new amoxicillin/clavulanate extra strength formulation (A/C 141) in the treatment of acute otitis media
22. Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis
23. The bacteriologic and clinical efficacy of high-dose amoxicillin (80 mg/kg/day tid) as first-line therapy for acute otitis media in children
24. Comparison of cyclacillin and amoxicillin for therapy for acute maxillary sinusitis
25. Comparative evaluation of cefuroxime axetil and cefaclor for treatment of acute bacterial maxillary sinusitis
26. Practice guidelines for the management of community-acquired pneumonia in adults
27. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - A report from the Drug-Resistant Streptococcus pneurnoniae Working Group
28. Management of community-acquired pneumonia in the era of pneumococcal resistance
29. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
30. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
31. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis
32. Meningitis with betalactam resistant Streptococcus pneumoniae: The need for early repeat lumbar puncture
33. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
34. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
35. Pharmacokinetics of a new extended-release clarithromycin tablet at doses of 500 and 1000 mg daily
36. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis
37. Comparative in-vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci
38. In-vivo pharmacodynamics of ABT-773, a new ketolide antibiotic
39. Comparative in-vivo activity of HMR 3647, azithromycin, clarithromycin, and roxithromycin against S. pneumoniae and S. aureus
40. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
41. Pharmacodynamics in the study of drug resistance and establishing in-vitro susceptibility breakpoints: Ready for prime time
42. A use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution
43. Mutation frequencies and antibiotic resistance
44. Limiting the spread of resistant pneumococci: Biological and epidemiologic evidence for the effectiveness of alternative interventions
45. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
46. Selection of aminoglycoside resistant variants of Pseudomonas aeruginosa in an in vivo model
47. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections
48. Effect of amoxicillin-clavulanate 14:1 vs. azithromycin on nasopharyngeal carriage and resistance of S. pneurnoniae
49. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae
50. Impact of azithromycin on oropharyngeal carriage of Group A Streptococcus and nasopharyngeal carriage of macrolide-resistant Streptococcus pneumoniae
51. Breakthrough sepsis in macrolide resistant pneumococcal infection